Work Here?
About Tr1X
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$75M
Headquarters
San Diego, California
Founded
2018
Overview
Tr1X focuses on developing cellular immunotherapies aimed at treating autoimmune and inflammatory diseases. The company uses a unique platform to create cell therapy products that help to rebalance the immune system and restore balance within the body, which can lead to long-lasting tolerance to these diseases. Unlike many other companies in the biopharmaceutical sector, Tr1X specializes in first-in-class therapies that target the underlying immune dysfunction rather than just managing symptoms. The goal of Tr1X is to provide advanced therapeutic solutions that improve the quality of life for patients suffering from these challenging conditions.
Simplify's Take
What believers are saying
- Tr1X received an $8M grant for TRX103 GvHD trial, boosting development.
- FDA clearance for TRX103 IND accelerates clinical trial progress in 2024.
- $75M Series A funding supports rapid advancement of Tr1X's cell therapies.
What critics are saying
- Emerging competition from companies like Sangamo Therapeutics threatens market share.
- Regulatory scrutiny on cell therapies could delay Tr1X's approval timelines.
- High development costs may strain finances without additional funding rounds.
What makes Tr1X unique
- Tr1X uses a proprietary platform for novel cellular immunotherapies.
- Their TRX103 therapy is a first-in-class allogeneic engineered Treg cell product.
- Tr1X focuses on autoimmune and inflammatory diseases with unique cell therapy solutions.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$75M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
401(k) Company Match
Flexible Work Hours
Stock Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -7%1 year growth
↑ 0%2 year growth
↓ -5%TR1X awarded $8M grant for TRX103 GvHD trial.
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix"), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials. The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of RD at Tr1X, with patients enrolling at leading stem cell transplant centers across the country. The trial is designed to treat patients receiving a mismatched or haploidentical transplant with a one-time infusion of TRX103. The Company has reported positive initial persistence and safety data in the first two patient cohorts, with additional data anticipated to be reported in 2025
Tr1X is developing TRX103 for the treatment of several immune and inflammatory disorders.
Company to initiate Phase 1 study of Graft versus Host Disease (GvHD) prevention in patients undergoing hematopoietic stem cell transplantation in Q2 2024Second IND application for refractory Crohn's disease expected in Q3 2024Highly scalable platform enables efficient pipeline expansion and opportunity beyond first two indicationsSAN DIEGO, April 10, 2024 /PRNewswire/ -- Tr1X, Inc., an autoimmune and inflammatory disease cell therapy company focused on the development of novel allogeneic regulatory T cell therapies (Allo-Tregs) and allogeneic regulatory T cells expressing Chimeric Antigen Receptors (Allo-CAR Tregs), today announced the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for TRX103 for the prevention of Graft versus Host Disease (GvHD) in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). The company plans to initiate a Phase 1 study of TRX103, an investigational allogeneic off-the-shelf Tr1 Treg therapy, for this indication in the second quarter of 2024. Additionally, the company is on track to submit an IND for TRX103 for patients with refractory Crohn's disease in the third quarter of 2024."The FDA's clearance of our IND for TRX103, the first ever allogeneic engineered Tr1 regulatory T cell product, is an important milestone that could quickly provide us with proof-of-concept data while we continue to develop TRX103 for multiple autoimmune and inflammatory diseases, including Crohn's disease," said Maria Grazia Roncarolo M.D., Co-Founder, President and Head of R&D at Tr1X. "Donor-derived autologous Tr1 cells have shown clinical promise in improving immune reconstitution and reducing GvHD but have limited potential due to lack of feasibility and high cost. TRX103, an off-the-shelf product with unique biological properties compared to other Treg and CAR-T cell therapies, has the potential to reduce inflammation, suppress pathogenic cells, and reset the immune system
Cell therapy startup Tr1X emerges from stealth with $75M Series A.
Tr1X is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Tr1X
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$75M
Headquarters
San Diego, California
Founded
2018
Tr1X is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today